Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XmAb18968 in Relapsed/Refractory CD38+ Acute Leukemia and T-LBL
NCT05038644Phase 1Terminated
- Start
- Feb 2022
- Primary completion
- Apr 2024
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of XmAb18968 in acute myeloid leukemia (AML), T cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) (10 arms). Primary endpoints: Dose-Limiting Toxicity at 42 days and Recommended Phase 2 Dose at 4 years. Started Feb 2022; status: terminated.
02
Drugs
XmAb18968
03
Conditions
acute myeloid leukemia (AML)T cell acute lymphoblastic leukemia (T-ALL)T-cell lymphoblastic lymphoma (T-LBL)
Beyond the preview
Go deeper on NCT05038644.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05038644.